Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy.
about
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapyVoltage-dependent anion channel 1-based peptides interact with Bcl-2 to prevent antiapoptotic activity.Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1Autophagy activation aggravates neuronal injury in the hippocampus of vascular dementia rats.A novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production.Regulated cell death pathways: new twists in modulation of BCL2 family functionG3139 (Genasense) in patients with advanced merkel cell carcinomaAutophagy upregulation and apoptosis downregulation in DAHP and triptolide treated cerebral ischemiaThe mitochondrial death pathway: a promising therapeutic target in diseasesTargeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.The apoptosome: emerging insights and new potential targets for drug designTherapeutic targets in the mitochondrial apoptotic pathway.Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysisTargeted therapies in small-cell lung cancer.Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling.Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?Endogenous knockdown of survivin improves chemotherapeutic response in ALL models.Bcl2 family proteins in carcinogenesis and the treatment of cancer.The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens.The protective mechanism of schisandrin A in d-galactosamine-induced acute liver injury through activation of autophagy.Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy.Effective treatment of leukemic cell lines with wt1 siRNA.Recent progress in oligonucleotide therapeutics: antisense to aptamers.The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia.
P2860
Q24635408-8F6C7967-28C7-4763-BCC5-F82FA7E81815Q33673430-6F0CE198-D9CE-44D8-BFD5-89ACB07A7F2DQ34123184-3E929126-9853-437E-9FAB-A7DE100F2C6FQ34163170-145E0264-60E5-4CAD-B249-58FB5F62CE17Q34414191-79B4051A-8C6F-437B-9823-09D6AAD33507Q34967337-2BD4071A-29FB-413D-B2F5-F2BD53742B62Q35029577-0EEECBE9-1520-428E-BBCE-151E4C1A16ADQ35097656-163A5F53-134C-4452-B18C-9A0B948FBD69Q35831981-8BAAFCE2-E118-4430-B5D5-A43BD73B6BAEQ36512593-B1BDB2B5-C7BF-4DC2-AA5B-3B931BD483C4Q36517696-4D806D02-87BB-420E-A4C8-6EF18E430923Q36764882-411FDA21-3DB9-41BC-BD80-1FA62E88F679Q36845783-4F359789-3776-4960-966E-18A528E37695Q36897340-B4457450-9338-4616-B4C3-E8833D1BDC53Q36897348-510F5733-B8F9-4A82-91E2-1276FC2261CAQ37023777-4C5135CC-DDF7-4776-96CD-16CB22EFC670Q37120213-7503CC04-774F-4D73-8B4B-1DF19FC5C61EQ37189998-47BE1580-826D-4F17-8211-5785E0B28308Q37324196-DD64E4D1-B727-4200-B743-E5C1E0A7ADBDQ37373448-61B8910B-A439-4F7F-8FD9-CC03720C1157Q37838167-63825847-B5F2-4BB9-82EB-0AC45FBF00D1Q39165281-0DED3015-04E9-4C86-BE47-61C7922075B2Q39868906-26E2B2D0-F7A9-4660-BCF8-2A446C4A62B4Q40095623-38120DD9-2BBF-425D-8286-3EDBA5BF9F58Q47563314-EEA390DE-A82D-4523-849A-3F27EA3F240EQ54385532-92A4D43A-0F3B-4E58-9F39-47335CC03493
P2860
Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Antisense and nonantisense eff ...... osensitizer in cancer therapy.
@ast
Antisense and nonantisense eff ...... osensitizer in cancer therapy.
@en
type
label
Antisense and nonantisense eff ...... osensitizer in cancer therapy.
@ast
Antisense and nonantisense eff ...... osensitizer in cancer therapy.
@en
prefLabel
Antisense and nonantisense eff ...... osensitizer in cancer therapy.
@ast
Antisense and nonantisense eff ...... osensitizer in cancer therapy.
@en
P2093
P2860
P356
P1433
P1476
Antisense and nonantisense eff ...... osensitizer in cancer therapy.
@en
P2093
P2860
P2888
P356
10.1038/SJ.CGT.7700986
P577
2006-10-13T00:00:00Z
P5875
P6179
1030620533